Skip to main content
Fig. 5 | Malaria Journal

Fig. 5

From: New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission

Fig. 5

Pfs25-specific serum antibody response upon heterologous prime-boost vaccination. a Vaccination schematic. Mice (n = 6 per group) were immunized with yPfs25-alum (2.5 μg/mouse) or Ad5 vector Pfs25 (109 particles) on day 0, and followed by boost immunization with yPfs25-alum (2.5 μg/mouse) or the different Ad5-HVR-pfs25 vectors (1010 particles). The serum samples were collected 21 days after the boost. b yPfs25-specific antibody titer. yPfs25-specific ELISA was performed and data depict pooled serum from 6 animals per group tested in triplicate in 3 independent ELISAs. The average ELISA unit and standard deviation are plotted. c yPfs25-specific antibody avidity. The assay was performed as described for Fig. 3. The fraction of Ig bound was determined by dividing the OD at each NaSCN concentration by the OD in the absence of NaSCN and the nonlinear best-fit line was plotted for each data set. d, e yPfs25-specific IgG sublass profile. The assay was performed as described for Fig. 3. The average OD and standard deviation for each isotype/subclass (d) and the ratio of the O.D. for the IgG1 to the O.D.s of IgG2b and IgG3 (e) are shown. Data depict the ratio of the OD for IgG1 to the ODs of IgG2b and IgG3

Back to article page